Trial reportFrontiers in cellular and infection microbiology2021
Effects of Oral Liposomal Glutathione in Altering the Immune Responses Against
Trial report in Frontiers in cellular and infection microbiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.
- Pooled it
- Glutathione-Mediated Redox Regulation of Immune Dysfunction in COVID-19 and Tuberculosis.Antioxidants (Basel, Switzerland) · 2026Review
- Liposome-Based Drug Delivery for Diabetes: Therapeutic Applications and a Nanomedicine Perspective on Diabetic Complications.International journal of nanomedicine · 2026Review
- Anti-TB treatment outcomes in TB meningitis: A systematic review and meta-analysis.New microbes and new infections · 2025Review
- Liposome-Encapsulated Antibiotics for the Therapy of Mycobacterial Infections.Antibiotics (Basel, Switzerland) · 2025Review
- Host-directed therapy for tuberculosis.European journal of medical research · 2025Review
- Challenges of Multidrug-Resistant Tuberculosis Meningitis: Current Treatments and the Role of Glutathione as an Adjunct Therapy.Vaccines · 2024Review
- The Role of mTOR inBiomedicines · 2024Review
- Immune Responses toBiomedicines · 2024Article
- Glutathione in HIV-Associated Neurocognitive Disorders.Current issues in molecular biology · 2024Review
- Liposomal Glutathione Augments Immune Defenses against Respiratory Syncytial Virus in Neonatal Mice Exposed in Utero to Ethanol.Antioxidants (Basel, Switzerland) · 2024Article
- An Update on Glutathione's Biosynthesis, Metabolism, Functions, and Medicinal Purposes.Current medicinal chemistry · 2024Review
- Role of Oxidative Stress in Tuberculosis Meningitis Infection in Diabetics.Biomedicines · 2023Review
- Topical Absorption of Glutathione-Cyclodextrin Nanoparticle Complex in Healthy Human Subjects Improves Immune Response againstAntioxidants (Basel, Switzerland) · 2023Article
- Glutathione Modulates Efficacious Changes in the Immune Response against Tuberculosis.Biomedicines · 2023Review
- The Role of Glutathione in Prevention of COVID-19 Immunothrombosis: A Review.Frontiers in bioscience (Landmark edition) · 2023Review
- The association between type 2 diabetes and pulmonary cavitation revealed among IGRA-positive tuberculosis patients.Frontiers in medicine · 2023Article
- Host-directed therapy against mycobacterium tuberculosis infections with diabetes mellitus.Frontiers in immunology · 2023Review
- Liposomal Glutathione Helps to MitigateAntioxidants (Basel, Switzerland) · 2022Article
- Modulating macrophage function to reinforce host innate resistance againstFrontiers in immunology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 1 institution in 1 country.
Funding
Abstract
The World Health Organization (WHO) has identified type 2 diabetes (T2DM) as a neglected, important, and re-emerging risk factor for tuberculosis (TB), especially in low and middle-income countries where TB is endemic. In this clinical trial study, oral liposomal glutathione supplementation (L-GSH) or placebo was given to individuals with T2DM to investigate the therapeutic effects of L-GSH supplementation. We report that L-GSH supplementation for 3 months in people with T2DM was able to reduce the levels of oxidative stress in all blood components and prevent depletion of glutathione (GSH) in this population known to be GSH deficient. Additionally, L-GSH supplementation significantly reduced the burden of intracellular mycobacteria within
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.